




PRACTICE AID

NCCN Clinical Practice Guidelines: Unresectable and Metastatic Cholangiocarcinoma¹

Full abbreviations, accreditation, and disclosure information available at [PeerView.com/FKB40](https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf)

PeerView
Oncology





PRACTICE AID

Selected Targeted Therapies in Biliary Cancers¹⁻¹³

Full abbreviations, accreditation, and disclosure information available at [PeerView.com/FKB40](https://www.peerview.com/FKB40)

PeerView
Oncology



 Target	 Agent	 Efficacy	 Safety <i>(Common Adverse Events)</i>
IDH	Ivosidenib	ClarIDHy mPFS: 2.7 mo; mOS: 10.3 mo	Nausea, diarrhea, fatigue, abdominal pain, ascites ^a
FGFR	Pemigatinib	FIGHT-202 mPFS: 7 mo; mOS: 17.5 mo	Hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea ^a
	Infigratinib	Phase 2 trial mPFS: 7.3 mo; mOS: 12.2 mo	Hyperphosphatemia, nail toxicity, stomatitis, dry eye, eye toxicity, fatigue ^a
	Futibatinib	FOENIX-CCA3 mPFS: 8.9 mo; mOS: 20 mo	Hyperphosphatemia, diarrhea, dry mouth
	Derazantinib	Phase 1/2 trial mPFS: 8 mo; mOS: 16 mo	Asthenia/fatigue, eye toxicity, hyperphosphatemia
	Erdafitinib	Phase 1 trial mPFS: 5.6 mo; mOS: NR	Hyperphosphatemia, dry mouth, asthenia
KRAS/BRAF/MEK/ERK pathway	Dabrafenib + trametinib	ROAR mPFS: 9 mo; mOS: 14 mo	Increased γ -glutamyltransferase, pyrexia
Antiangiogenic agents	Lenvatinib	LEAP-005 mPFS: 6.1 mo; mOS: 8.6 mo	Hypertension, dysphonia, diarrhea, fatigue, nausea



PRACTICE AID

Selected Targeted Therapies in Biliary Cancers¹⁴⁻¹⁷

Full abbreviations, accreditation, and disclosure information available at [PeerView.com/FKB40](https://www.peerview.com/FKB40)

PeerView
Oncology



 Target	 Agent	 Efficacy	 Safety <i>(Common Adverse Events)</i>
HER2	Pertuzumab + trastuzumab	MyPathway (gallbladder) mPFS: 4.2 mo; mOS: 14.2 mo	Elevated liver enzymes, increased bilirubin
	Clinical note on emerging HER2 agents: Zanidatamab is a <i>HER2</i> -bispecific antibody currently in development and has shown activity in the HERIZON-BTC-01 trial in <i>HER2</i> -positive BTC (NCT04466891)		
TRK	Larotrectinib	FDA approved mPFS: 29.4 mo; mOS: NR	Elevated liver enzymes, nausea, dizziness, constipation
	Entrectinib	FDA approved mPFS: 13.8 mo; mOS: 37.1 mo	Dysgeusia, constipation, fatigue, diarrhea, peripheral edema, dizziness

* Selected adverse events. Please see full prescribing information for a complete list.

1. Abou-Alfa GK et al. *Lancet Oncol.* 2020;21:796-807. 2. Tibsovo (ivosidenib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. 3. Javle M et al. ESMO 2018. Abstract LBA 28. 4. Hollebecque A et al. *Ann Oncol.* 2018;29(suppl 8):viii205-viii270. 5. Saleh M et al. *Mol Cancer Ther.* 2018;17(1 suppl):A098. 6. Mazzaferro V et al. *J Clin Oncol.* 2017;35(15 suppl):4017. 7. Mazzaferro V et al. *Br J Cancer.* 2019;120:165-171. 8. Goyal L et al. *Cancer Treatment Reviews.* 2021;95:102170. 9. Kuboki Y et al. *Ann Oncol.* 2017;28(suppl 5):mdx367.006. 10. Meric-Bernstam F et al. ESMO 2018. Abstract O-001. 11. Chen Y-Y et al. *Ann Oncol.* 2018;29:mdy282.008. 12. Subbiah V et al. *Lancet Oncol.* 2020;21:1234-1243. 13. Villanueva L et al. ASCO 2021. Abstract 4080. 14. Javle M et al. *Lancet Oncol.* 2021;22:1290-1300. 15. <https://clinicaltrials.gov/ct2/show/NCT04466891>. 16. Drilon A et al. ASCO 2022. Abstract 3100. 17. Krzakowski MJ et al. ASCO 2022. Abstract 3099.



Tools and Resources for Engagement With Patients With BTC¹

PeerView
Oncology



Full abbreviations, accreditation, and disclosure information available at
PeerView.com/FKB40

Patient-centered education is vital to optimizing outcomes in patients with biliary tract cancers (BTCs).

The printable resource on the following page is for you to share with patients and caregivers. It outlines helpful support options provided by the Cholangiocarcinoma Foundation.



Printable Resource on Next Page

1. <https://cholangiocarcinoma.org/mutationsmatter/patients-portal>.

Have you or your loved one been diagnosed with a bile duct cancer?

Patient Education

The below resources from the Cholangiocarcinoma Foundation may help support you on the treatment journey.

The Cholangiocarcinoma Foundation's (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer).



Visit <https://cholangiocarcinoma.org/> for multiple resources that patients can use to:


- Get the latest information about their disease
- Connect with other patients
- Participate in clinical trials
- And much more

Selected resources include:




International Cholangiocarcinoma Patient Registry (ICPR)

<https://cholangiocarcinoma.org/international-cholangiocarcinoma-patient-registry-icpr/>



Find a Specialist

<https://cholangiocarcinoma.org/specialist-map/>



Find and Learn About Clinical Trials

<https://cholangiocarcinoma.org/professionals/research/clinical-trials/>

Always contact your healthcare provider or care team with specific questions or concerns